(Date:1/8/2009)...panese testing reveals longer protection from naus...althDay News) -- A drug that better prevents the n...apy treatment for cancer may be on the horizon, Ja...a doctor at Juntendo University Hospital in Tokyo ...as the common anti-nausea drug granisetron at avoi...
(Date:1/8/2009)..., March 18-19 Session in Orlando Will Feature ...ncy, Brand Loyalty and Plan Profitability , , ...recedented marketplace disruption - ranging from t...o greater consumer autonomy in health insurance se...oup plan members is now a priority for the nation,...
(Date:1/8/2009)..., MOUNT ROYAL, N.J., Jan. 8 Th...ation (HCMA) today announced that its second annua...at the new Westin Hotel in Jersey City,N.J. from...ill focus on a,single directive: shaping the futu... device, pharmaceutical, biotechnology, diagnostic...
(Date:1/8/2009)..., SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire-Firs... PARD ), a biopharmaceutical company focused on,...verview of its 2009 clinical,goals for developmen...latin is,a new generation platinum-based chemothe...m product addressing multiple indications, combina...
Breaking Medicine News(10 mins):Health News:World Health Care Congress and ConnextionsHealth Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 2Health News:World Health Care Congress and ConnextionsHealth Will Host Leadership Summit to Address Member Retention for Health Insurance Plans 3Health News:The Healthcare Communication & Marketing Association Announces June 2009 Conference and IN-AWE and Delta Awards Ceremony 2Health News:Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin 2Health News:Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin 3Health News:Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin 4Health News:Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin 5...cted patients rose Saturday to 1,772 in Pakistan, ...wspaper The News. // In the last 24 hours, 19 new...s and symptoms of dengue fever from Islamabad and ...tistics of Pakistani National Institute of Health,...
...lation and operation of a modern cyclotron - which...n India//. The Variable Energy Cyclotron Centre ...gy (BRIT) of the department of atomic energy will ... useful radioisotopes. Ion beams from cyclotrons c...
...se (FMD) were carried out at the abattoir where th...after the tests on pigs proved// negative at the C... In order to prevent the possible spread of FMD, ...s within a five-mile radius of the slaughterhouse ...
...Healthcare products Regulatory Agency amended lice...ith the amendment it is now possible to market hom...ribe the name and therapeutic application of remed...mong conventional medical professionals who have w...
Other Medicine News:Health News:Hostility breeds against Homeopathy in England following new regulations 2(Date:1/6/2009)... N.J., Jan. 6 Pacira Pharmaceutica...company, announced today that enrollment,has been...to evaluate the,safety and efficacy of a single i...Bupivacaine) for prolonged postoperative analgesia...ctomy and in total knee,arthroplasty (TKA) are ex...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswire-US... growing technology providing an increasing number...of back pain according to an article in the Januar...y of Orthopaedic Surgeons ( http://www.jaaos.org/ ...rs, additional technical developments will allow M...
(Date:12/27/2008)...lier breaks 5-year silence, offers to ease cloning... , LAS VEGAS, Dec. 27 ... the first cloned child, Dr. Brigitte Boisselier, ..., said Eve and other babies cloned by her company ...e invading their families, privacy. , , "We,ve ...
(Date:12/17/2008)... 17 Medivation, Inc.,(N...ted patient enrollment in a,Phase 1-2 dose-escala...,receptor antagonist, in castration-resistant pro...oval from the U.S. Food and Drug Administration (F...ar. , The open-label, U.S. Phase 1-2 study ...
Breaking Medicine Technology:Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3'We're Ready to Prove It!' 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4California Affiliates of Susan G Komen for the Cure Convene Celebrities Breast Cancer Survivors and Activists to Challenge Elected Officials to Stre 9521 1California Affiliates of Susan G Komen for the Cure Convene Celebrities Breast Cancer Survivors and Activists to Challenge Elected Officials to Stre 9521 2California Affiliates of Susan G Komen for the Cure Convene Celebrities Breast Cancer Survivors and Activists to Challenge Elected Officials to Stre 9521 3GBC Seeks Nominations for Regions Third Annual Bioscience Awards 2584 1Bookham to Enter Biomedical Illumination Market 2581 1Bookham to Enter Biomedical Illumination Market 2581 2Bookham to Enter Biomedical Illumination Market 2581 3Roche responds to announcement of IDEAL hepatitis C trial results 1194 1Roche responds to announcement of IDEAL hepatitis C trial results 1194 2Roche responds to announcement of IDEAL hepatitis C trial results 1194 3Roche responds to announcement of IDEAL hepatitis C trial results 1194 4Roche responds to announcement of IDEAL hepatitis C trial results 1194 5Roche responds to announcement of IDEAL hepatitis C trial results 1194 6Roche responds to announcement of IDEAL hepatitis C trial results 1194 7...BRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Bio...one-year data presented at the,Academy of Managed ...at AVONEX(R) (Interferon beta-1a) is a cost-effect...ed to other interferon beta,treatments. Using a co..., the results of the research concluded that patie...
...BRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dya...line results from its,Phase 3, placebo-controlled ...8 (ecallantide), for hereditary angioedema (HAE). ...uled for Tuesday,April 17, 2007 at 12:30 p.m. ET....asma kallikrein,inhibitor, is in clinical trials f...
Other Medicine Technology:New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 2New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis 3DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 2DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 3DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 4DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3) 5...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: